Every year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 deliver windfall surprises for European names?
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2020-04-08 10:07:502020-04-08 10:07:50Sutura Therapeutics: New CEO
Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
https://european-biotechnology.com/wp-content/uploads/2024/04/Lady_with_Solnatide_vials_in_production.jpg19251921Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-04-08 09:20:562020-04-08 09:20:56COVID-19: Solnatide approved for compassionate use
In October 2019, Thierry Bernard provisionally took over the responsibilities of Qiagen CEO Peer Schatz, who had left the company unexpectedly after 27 years.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2020-04-01 12:16:342020-04-01 12:16:34Qiagen: Thierry Bernard remains CEO
https://european-biotechnology.com/wp-content/uploads/2024/04/FFG.jpg186270Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2020-04-01 09:06:542020-04-01 09:06:54Apeptico gets EU grant for COVID-19 drug
Researchers reconstruct SARS-CoV-2 evolution
Latest NewsBritish researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US.
European assets ahead despite virus panic
OpinionEvery year, it’s the same: in January, investors are scratching their heads, searching to find investment ideas that could ensure the greatest return/performance. Given the current valuation, can 2020 deliver windfall surprises for European names?
Sutura Therapeutics: New CEO
AppointmentsMark Beards is the new CEO of Sutura Therapeutics Ltd in Birkenhead (UK).
COVID-19: Solnatide approved for compassionate use
Latest NewsAustrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.
GE renamed Cytiva upon take-over by Danaher
Latest NewsMaking opoids more effective pain killers
Latest NewsLow intrinsic efficacy can explain the reduced side effects of new agonists of the m-opioid receptor a British-Australian reseach team reports.
Qiagen: Thierry Bernard remains CEO
AppointmentsIn October 2019, Thierry Bernard provisionally took over the responsibilities of Qiagen CEO Peer Schatz, who had left the company unexpectedly after 27 years.
Apeptico gets EU grant for COVID-19 drug
Latest NewsAustrian APEPTICO has got Horizon 2020 money for accelerated development and clinical use of Solnatide for the treatment of COVID-19 patients
CHMP greenlights Novartis’ Zolgensma
Latest NewsThe European Medicines Agency EMA has backed eight medicines for approval at its virtual March 2020 meeting.
New resource models human metabolism
Latest NewsScandinavian researchers have created a unified, open-source model providing a genome-wide portrait of human disease metabolism.